Supplemental Table 1. Baseline characteristics in patients with critical limb ischemia (CLI) with and without major adverse limb events (MALE) in validation cohort of KMUH cohort (N = 179).
| Variable | All population (N= 179) | MALE (-) (N= 130) | MALE (+) (N= 49) | P value |
|---|---|---|---|---|
| Age (y/o) | 69.1±11.3 | 68.5±11.1 | 70.2±11.9 | 0.51 |
| Age ＞75 y/o, n (%) | 64 (35.7) | 42 (32.3) | 22 (44.9) | 0.16 |
| Age ＞65 y/o, n (%) | 122 (68.2) | 85 (65.3) | 37 (75.5) | 0.05 |
| Men, n (%) | 84 (41.3) | 51 (39.2) | 23 (46.9) | 0.39 |
| BMI (kg/M2) | 24.5±4.3 | 24.6±4.3 | 24.3±4.5 | 0.58 |
| BMI ＞25, n (%) | 68 (37.9) | 52 (40) | 16 (32.6) | 0.39 |
| BMI ＞30, n (%) | 17 (9.5) | 13 (10) | 4 (8.1) | 0.47 |
| Medical history | ||||
| Hypertension, n (%) | 138 (77.1) | 103 (79.2) | 35 (71.4) | 0.32 |
| Diabetes, n (%) | 120 (67) | 82 (63.1) | 38 (77.5) | 0.04 |
| Hyperlipidemia, n (%) | 12 (6.7) | 12 (9.2) | 0 (0) | 0.69 |
| CAD, n (%) | 15 (8.4) | 11 (8.4) | 4 (8.1) | 0.37 |
| Previous stroke, n (%) | 2 (1.1) | 2 (1.5) | 0 (0) | 0.67 |
| HF, n (%) | 3 (1.6) | 1 (0.7) | 2 (4) | 0.17 |
| Atrial fibrillation, n (%) | 27 (15) | 23 (17.7) | 4 (8.2) | 0.16 |
| Cancer, n (%) | 15 (8.4) | 12 (9.2) | 3 (6.1) | 0.76 |
| Smoking, n (%) | 32 (17.8) | 93 (71.5) | 32 (65.3) | 0.06 |
| Lab data | ||||
| eGFR(ml/min/1.73 2) | 36.8±36.8 | 38.6±38.5 | 33.2±22.3 | 0.04 |
| CKD (eGFR ＜60) , n (%) | 140 (78.2) | 100 (76.9) | 40 (81.6) | 0.54 |
| Fasting glucose (mg/dl) | 175.1±81.2 | 158.3±67.9 | 129.7±49.1 | 0.4 |
| Cholesterol (mg/dl) | 159.3±28.7 | 136.6±56.7 | 189±25.4 | 0.48 |
| LDL (mg/dl) | 96.9±24.9 | 93.1±24.2 | 124 ±7.1 | 0.17 |
| TG (mg/dl) | 142.8±56.2 | 154±27.3 | 186.3±21.5 | 0.24 |
| Cardiovascular drugs | ||||
| Aspirin, n (%) | 59 (32.9) | 49 (37.6) | 10 (20.4) | 0.54 |
| Cilostazol, n (%) | 59 (32.9) | 46 (35.3) | 13 (26.5) | 0.11 |
| ACEI/ARB, n (%) | 67 (37.4) | 48 (36.9) | 19 (38.7) | 0.86 |
| Statins, n (%) | 78 (43.5) | 55 (42.3) | 23 (46.9) | 0.61 |
| CYP2C19*2 allele | ||||
| None, n (%) | 82 (45.8) | 66 (50.7) | 16 (32.6) | 0.001 |
| One allele, n (%) | 94 (52.5) | 64 (50) | 30 (61.2) | 0.04 |
| Two alleles, n (%) | 3 (1.7) | 0 (0) | 3 (6.1) | 0.02 |
Abbreviation as listed in Table 1